EUCTR2016-000617-67-IT进行中（未招募）1 期
A phase II study to investigate the activity and safety of anti-PD-L1 antibody (Durvalumab) In ADvancEd pretreated malignant pleural Mesothelioma - DIADEM Study - DIADEM
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI0 个研究点目标入组 57 人开始时间: 2018年10月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Cytological or histological diagnosis of
- •unresectable MPM (advanced or inoperable);
- •2.Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or at least 15 unstained slides for central determination of PD-L1 expression;
- •3.Aged = 18 years;
- •4.Performance status 0-2 (ECOG);
- •5.Measurable disease as defined by Modified RECIST v1.1 for MPM;
- •6.One previous chemotherapy line for MPM of pemetrexed plus platinum derivative;
- •7.Previous chemotherapy course concluded at least 4 weeks prior to recruitment;
- •8.Signed informed consent;
- •9.Negative pregnancy test. All patients in reproductive age or potential must agree to use effective contraception, as defined by the study protocol for the entire duration of treatment with study drug and for 3 months following its interruption;
- •10.Patients who have received palliative radiation are eligible if <30% of bone marrow was irradiated and normal hematological function was completely regained;
- •11.Adequate organ and marrow function as defined below: Haemoglobin = 9.0 g/dL, Absolute neutrophil count (ANC) = 1.5 x 109/L (> 1500 per mm3), Platelet count = 100 x 109/L (>100,000 per mm3);
- •12.Adequate liver function: Serum bilirubin = 1.5 x institutional upper limit of normal (ULN) (except for patients confirmed Gilbert’s syndrome, who will be allowed only in consultation with their physician); AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be = 5x ULN;
- •13.Adequate renal function: Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria:
- •1.Radiotherapy with curative intent to thoracic wall (concomitant with or prior to chemotherapy);
- •2.Severe concomitant illness;
- •3.History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, type I diabetes mellitus, vasculitis, or glomerulonephritis;
- •4.Enrolment in other trials;
- •5.Any other anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent);
- •6.Active or prior documented inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis);
- •7.History of primary immunodeficiency;
- •8.HIV, TB, HBV or HCV infection (HBsAg+; HCV-RNA+);
- •9.History of allogeneic organ transplant;
- •10.History of hypersensitivity to durvalumab or any excipient;
- •11.Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving Durvalumab;
- •12.Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results;
- •13.History of other malignancies (except basal cell carcinoma or cervical carcinoma in situ, adequately treated), unless in remission for 5 years or more and judged of negligible potential of relapse;
- •14.Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within one year before enrolment, uncontrolled arterial hypertension or arrhythmias;
- •15.Brain / leptomeningeal involvement;
- •16.Any previous treatment with a PD-1 or PD-L1 inhibitor, including Durvalumab;
- •17.Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- •18.AEs from prior anticancer therapy that have not resolved to grade = 1 except for alopecia
研究者
相似试验
进行中（未招募）
不适用
A randomized phase II study to assess the activity and tolerability of two regimens of metronomic oral chemotherapy methotrexate plus cyclophosphamide and cyclophosphamide plus capecitabine combined with bevacizumab in advanced breast cancer - NDEUCTR2005-005046-39-ITISTITUTO EUROPEO DI ONCOLOGIA92
进行中（未招募）
1 期
A clinical trial to test how the study medication (SMT C1100) works and how safe it is when given to children with Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2015-004333-27-GBSummit (Oxford) Limited43
进行中（未招募）
不适用
A PILOT, PHASE II, MONOCENTRIC STUDY WITHOUT A CONTROL GROUP, ON ACTIVITY AND SAFETY OF HOMEOPATIC MEDICINE ON CANCER RELATED FATIGUE (CRF) AND QUALITY OF LIFE IN PATIENTS UNDER CHEMOTHERAPYOncologic patientsMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002337-19-ITAZIENDA UNITA' SANITARIA LOCALE DI PARMA48
进行中（未招募）
不适用
Estudio piloto de fase IIb para evaluar la actividad antivírica de una pauta que contiene GSK1349572 en sujetos adultos infectados por el VIH-1 con resistencia al raltegravir que habían recibido tratamiento previo con antirretrovirales (ART) - VickingEUCTR2009-010270-37-ESGlaxoSmithKline S.A.30
进行中（未招募）
不适用
A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer PatientsPretreated patients with advanced colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019841-25-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI